Compare WGS & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WGS | QURE |
|---|---|---|
| Founded | 2017 | 1998 |
| Country | United States | Netherlands |
| Employees | 1300 | 248 |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | N/A | 2013 |
| Metric | WGS | QURE |
|---|---|---|
| Price | $65.62 | $43.49 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 14 |
| Target Price | ★ $120.71 | $45.00 |
| AVG Volume (30 Days) | 1.0M | ★ 2.9M |
| Earning Date | 05-04-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,107,000.00 |
| Revenue This Year | $29.98 | $126.12 |
| Revenue Next Year | $25.92 | $200.43 |
| P/E Ratio | $1,251.58 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $32.21 | $8.73 |
| 52 Week High | $170.87 | $71.50 |
| Indicator | WGS | QURE |
|---|---|---|
| Relative Strength Index (RSI) | 55.31 | 59.95 |
| Support Level | $55.76 | $22.20 |
| Resistance Level | $73.46 | $50.47 |
| Average True Range (ATR) | 4.39 | 3.47 |
| MACD | 0.02 | -0.81 |
| Stochastic Oscillator | 56.54 | 27.89 |
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.